Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr Reddy’s Steps Into 'Must-Be' Medical Cannabis Segment With German Deal

Executive Summary

Dr Reddy’s enters high-potential medical cannabis fray with the acquisition of Nimbus Health in Germany. The segment has seen a flurry of activity over the recent past, including the $7.2bn acquisition of pioneer GW Pharmaceuticals.

You may also be interested in...



Dr Reddy’s Continues To Capitalize On German Cannabinoids With MediCane Launch

Dr Reddy's has announced that it will market MediCane’s medical cannabis portfolio across Germany, as part of a collaboration between the two companies which began last year.

Stada Expands Supply Network With Romanian Facility

Stada is investing nearly €50m in a Romanian supply-chain hub that it says will support future growth for the company, benefiting from its central European location. Meanwhile, the company has also struck medical cannabis deals with German insurers AOK and IKK.

Neuraxpharm And Panaxia Take Cannabis Tablets To France

Neuraxpharm and Panaxia have continued to push forward with their partnership on medical cannabis, exporting sublingual tablets to France as part of a pilot program organized by local regulator ANSM.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel